|
| Wednesday, December 11, 2024 |
|
|
雲頂新耀：加速腎病領域創新 邁向全球生物製藥領先地位 |
| 據《南華早報》報導，雲頂新耀（HKEX 1952.HK）正加速實現其成為亞太地區領先生物製藥企業的願景。公司憑藉強大的研發實力與卓越的商業化能力，在持續推動業務發展的同時，不斷深化在全球生物製藥領域的佈局。 more info >> |
|
|
云顶新耀：加速肾病领域创新 迈向全球生物制药领先地位 |
| 据《南华早报》报道，云顶新耀（HKEX 1952.HK）正加速实现其成为亚太地区领先生物制药企业的愿景。公司凭借强大的研发实力与卓越的商业化能力，在持续推动业务发展的同时，不断深化在全球生物制药领域的布局。 more info >> |
|
| Wednesday, December 4, 2024 |
|
|
Everest Medicines Announces Positive Results in Preliminary Analysis of Phase 1b/2a Clinical Trial of EVER001, a Novel BTK Inhibitor for the Treatment of Primary Membranous Nephropathy |
| Everest Medicines (HKEX 1952.HK,"Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced positive results in the ongoing Phase 1b/2a clinical trial for the treatment of primary membranous nephropathy (pMN) with EVER001 (previously known as XNW1011), a next-generation covalent reversible Bruton's tyrosine kinase (BTK) inhibitor. more info >> |
|
|
雲頂新耀宣佈治療原發性膜性腎病的新型BTK抑制劑EVER001在1b/2a期臨床試驗階段性數據中取得積極結果 |
| 雲頂新耀（HKEX 1952.HK）是一家專注于創新藥研發、臨床開發、製造和商業化的生物製藥公司，今日宣佈新一代共價可逆布魯頓酪氨酸激酶（BTK）抑制劑EVER001膠囊（又名：XNW1011）在治療原發性膜性腎病（primary membranous nephropathy，pMN）的1b/2a期臨床試驗階段性資料取得積極結果。 more info >> |
|
|
云顶新耀宣布治疗原发性膜性肾病的新型BTK抑制剂EVER001在1b/2a期临床试验阶段性数据中取得积极结果 |
| 云顶新耀（HKEX 1952.HK）是一家专注于创新药研发、临床开发、制造和商业化的生物制药公司，今日宣布新一代共价可逆布鲁顿酪氨酸激酶（BTK）抑制剂 EVER001胶囊（又名：XNW1011）在治疗原发性膜性肾病（primary membranous nephropathy，pMN）的1b/2a期临床试验阶段性数据取得积极结果。 more info >> |
|
| Monday, December 2, 2024 |
|
|
Everest Medicines Announces Acceptance of VELSIPITY New Drug Application in Hong Kong |
| Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that Department of Health of the Government of the Hong Kong Special Administrative Region, China, has accepted Everests New Drug Application (NDA) for VELSIPITY (etrasimod) for the treatment of adult patients with moderately to severely active ulcerative colitis. more info >> |
|
|
雲頂新耀宣佈中國香港衛生署正式受理伊曲莫德（VELSIPITY(R)） |
| 雲頂新耀（HKEX 1952.HK）是一家專注于創新藥研發、臨床開發、製造和商業化的生物製藥公司，今日宣佈中國香港衛生署已正式受理伊曲莫德（VELSIPITY(R)）用於治療中重度活動性潰瘍性結腸炎成人患者的新藥上市許可申請（NDA）。 more info >> |
|
|
云顶新耀宣布中国香港卫生署正式受理伊曲莫德（VELSIPITY(R)） |
| 云顶新耀（HKEX 1952.HK）是一家专注于创新药研发、临床开发、制造和商业化的生物制药公司，今日宣布中国香港卫生署已正式受理伊曲莫德（VELSIPITY(R)）用于治疗中重度活动性溃疡性结肠炎成人患者的新药上市许可申请（NDA）。 more info >> |
|
| Friday, November 29, 2024 |
|
|
NEFECON(R) Included in National Reimbursement Drug List (NRDL) |
| On November 28, the National Healthcare Security Administration (NHSA) and the Ministry of Human Resources and Social Security announced the 'National Reimbursement Drug List (2024)' (NRDL), which will officially take effect on January 1, 2025. NEFECON(R), the first etiological treatment for IgA nephropathy developed by Everest Medicines, was successfully included in the NRDL. more info >> |
|
|
耐賦康(R)納入新版國家醫保藥品目錄 |
| 國家醫療保障局和人力資源與社會保障部發佈了《國家基本醫療保險、工傷保險和生育保險藥品目錄（2024年）》（以下簡稱「國家醫保藥品目錄」），並宣佈新版目錄將於2025年1月1日起正式實施。 more info >> |
|
|
|
|
